Thursday, 15th February – h. 14:00
Seminars Room, NICO
The role of the inflammation mediators gp130 receptor and sphingosine-1-phosphate in peripheral neuronal regeneration
Neurons are able to change their signaling pathway and network in order to react to warning signals in pathological conditions. The inflammation mediators, theIL-6 signal transducer gp130 and thebioactive lipid sphingosine-1-phosphate (S1P) play a dual role, not only in neuronal excitability and pain sensitivity but also in neuron regeneration after injury. Lack of g130 causes delay in sensory recovery in vivo after crush injury and reduced skin reinnervation.
Moreover, gp130 is found to be a determining factor for the growth promoting action of NGF in adult sensory neurons. The sphingolipid S1P has alsoa critical role in fine-tuning axonal outgrowth in sensory neurons and regeneration of peripheral fibers. S1P can indeed activate differentially GCPRs supporting neurite elongation or retraction depending by the cell needs.Modulation of the above signaling pathways through genetic modifications or pharmacological tools canimprove pathological states.
Host: Ferdinando Di Cunto
Le ultime novità nella Microscopia Correlativa Multi-modale. Registrazione obbligatoria.
Since 2001, this meeting represented an important event for basic and clinical researchers working on this emerging scientific topic. We will address state-of-the-art approaches in the field of steroids and nervous system, including behavior, epigenetics, genomic and non-genomic actions, the vitamin D, neurodegenerative and psychiatric disorders, and the interference among endocrine disruptors and steroid signaling.
L’inibizione della proteina JNK rallenta la progressione della malattia che colpisce i motoneuroni ed è la prima causa genetica di morte nell’infanzia. Lo dimostra uno studio pubblicato su Frontiers in Molecular Neuroscience dal nostro gruppo di ricerca guidato da Alessandro Vercelli, in collaborazione con l’Istituto Mario Negri di Milano. Chiarire i meccanismi molecolari alla base della SMA può aprire la strada allo sviluppo di nuove terapie.